Becker's Clinical Quality & Infection Control

March/April 2022 IC_CQ

Issue link: https://beckershealthcare.uberflip.com/i/1462389

Contents of this Issue

Navigation

Page 47 of 47

Nozin® Nasal Sanitizer® antiseptic is for nasal decolonization. ©2021 Global Life Technologies Corp. All rights reserved. Made in USA. Nozin®, Nasal Sanitizer®, Popswab®, NOVA SM and Nozaseptin® are trademarks of Global Life Technologies Corp. Nozin® Nasal Sanitizer® antiseptic is an OTC topical drug. No claim is made that it has an effect on any specific disease. Patent nos.: nozin.com/patents. Anatomy of the #1 Daily Nasal Decolonizer Nozin ® Nasal Sanitizer ® Antiseptic The right tool for MRSA / MSSA colonization risk mitigation programs Find out why so many facilities adopt the Nozin NOVA SM MRSA Colonization Risk Mitigation programs, powered by Nozin ® Nasal Sanitizer ® antiseptic. Contact Nozin for a NOVA SM MRSA risk mitigation analysis. Visit: nozin.com/nova Call: 877-669-4648 Proprietary Popswab ® advanced delivery & application system. Activation, saturation and application in 30 seconds, allowing full potency. Unique hermetically sealed device with double walled protection helps keep product fresh. Recharge feature fully saturates tip four times assuring both nostrils get full dose. Patented Nozaseptin ® formula. Nozin ® Nasal Sanitizer ® antiseptic kills pathogens on contact. 12-hour persistence. Moisturizing. Pleasant citrus scent. Convenient, ergonomic design – easy to use. Swab tip is not pre-saturated. It won't dry out or leach. Solution will not stain the skin. Comfortable soft tip. Gentle, porosity-controlled applicator tip. 15 years of safe, effective use. Millions of users. USP and GRAS ingredients. Extensive published third-party outcomes data. Industry leading results: Nozin.com/clinical-outcomes Easy-to-apply engineered sof t tip Herme tically sealed solution to maintain full potency Clinically proven patented formula Rechargeable tip can be re-saturated 4X for maximum coverage

Articles in this issue

Links on this page

view archives of Becker's Clinical Quality & Infection Control - March/April 2022 IC_CQ